Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Study of Panosyl-Isomaltooligosaccharides (PIMO) Adjunctive to Proton Pump Inhibitor (PPI) Therapy to Treat Gastroesophageal Reflux Disease (GERD) in Subjects Who Are PPI-Responders or PPI-Partial Responders

NCT05556824 is registered in ClinicalTrials.gov with Microbiome Health Sciences as lead sponsor.

NCT NCT05556824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05556824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Study of Panosyl-Isomaltooligosaccharides (PIMO) Adjunctive to Proton Pump Inhibitor (PPI) Therapy to Treat Gastroesophageal Reflux Disease (GERD) in Subjects Who Are PPI-Responders or PPI-Partial Responders
Lead sponsor
Microbiome Health Sciences
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2023
Completion date
May 27, 2026
Enrollment
255 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux